Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 98.16% | -49.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 98.16% | -49.11% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 98.16% | -49.11% | |||
| SG&A Expenses | 43.44% | -31.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.94% | 21.23% | |||
| Operating Income | 33.14% | -41.22% | |||
| Income Before Tax | -376.00% | -39.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -376.00% | -39.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -376.00% | -39.59% | |||
| EBIT | 33.14% | -41.22% | |||
| EBITDA | 33.58% | -41.98% | |||
| EPS Basic | -143.28% | -37.44% | |||
| Normalized Basic EPS | -142.00% | -37.45% | |||
| EPS Diluted | -143.28% | -37.44% | |||
| Normalized Diluted EPS | -142.00% | -37.45% | |||
| Average Basic Shares Outstanding | 95.66% | 1.55% | |||
| Average Diluted Shares Outstanding | 95.66% | 1.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||